AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Ectonucleotide pyrophosphatase/phosphodiesterase family member 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q13822

UPID:

ENPP2_HUMAN

Alternative names:

Autotaxin; Extracellular lysophospholipase D

Alternative UPACC:

Q13822; A8UHA1; E9PHP7; Q13827; Q14555; Q15117; Q9UCQ8; Q9UCR0; Q9UCR1; Q9UCR2; Q9UCR3; Q9UCR4

Background:

Ectonucleotide pyrophosphatase/phosphodiesterase family member 2, also known as Autotaxin or Extracellular lysophospholipase D, plays a pivotal role in the hydrolysis of lysophospholipids into lysophosphatidic acid (LPA), a key signaling molecule. This enzyme's major substrate is lysophosphatidylcholine. Beyond its enzymatic activity, it is involved in critical motility-related processes including angiogenesis, neurite outgrowth, and the stimulation of smooth muscle cell migration, contributing to microtubule formation. Autotaxin's ability to stimulate melanoma cell migration and its requirement for LPA production in activated platelets underscore its biological significance.

Therapeutic significance:

Understanding the role of Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 could open doors to potential therapeutic strategies, particularly in the realms of cancer treatment, cardiovascular diseases, and wound healing processes.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.